Escitalopram: Independent Evidence on Depression, GAD, Side Effects & Withdrawal

Table of contents

• Evidence summary
• What escitalopram is
• How it works
• What it is prescribed for
• What works and what does not
• Benefits by claim
• Risks and all side effects
• All interactions
• Who should avoid escitalopram
• Dosage and how to take it
• Follow the money: who makes it and who funded the evidence
• Related research
• Frequently asked questions
• Sources and funding notes

Evidence summary

This table lists the main claims made about escitalopram, ranked by the strength of the human evidence behind them. The funding column shows who paid for each source.

Independent evidence and credibility scorecard

Independence tiers: 1 = government regulator or public body; 2 = academic with no relevant industry funding; 3 = academic, but with some industry ties or a manufacturer-dominated trial base; 4 = manufacturer or seller. Credibility A–D reflects method quality plus independence.

What escitalopram is

Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. In the UK it is available only on prescription, and the NHS lists Cipralex as its common brand name (NHS). In the United States it is sold as Lexapro. The US label lists tablets (5, 10 and 20 mg) and an oral solution, and the product is a prescription drug (FDA label). In the UK, escitalopram comes as tablets, orodispersible tablets (which dissolve on the tongue) and oral drops (NHS).

Chemically, escitalopram is the S-enantiomer of citalopram. Citalopram is a 50:50 mix of two mirror-image molecules, and escitalopram contains only the active "S" half (MHRA). The US label says escitalopram is at least 100-fold more potent than the R-enantiomer at inhibiting serotonin reuptake (FDA label, 12.2).

• Originator: H. Lundbeck A/S, headquartered in Copenhagen (Valby), Denmark. The Cipralex UK licence holder is Lundbeck Limited, Watford (SmPC; Lundbeck).
• First approvals: the UK SmPC records a first authorisation date of 10 June 2002. The US FDA approved Lexapro (NDA 021323) on 14 August 2002. That application is now listed under AbbVie (Drugs@FDA).
• Generic status: generic escitalopram is widely available. Lundbeck attributes falling Cipralex/Lexapro sales to "continued generic erosion" (Lundbeck FY2025). FDA's label database lists 45 labellers of escitalopram prescription products, including generic makers such as Aurobindo Pharma and Amneal Pharmaceuticals, as well as repackagers (openFDA query).
• Legal category: prescription-only medicine (POM) in the UK (SmPC) and prescription-only (Rx) in the US.

How it works

Nerve cells release serotonin (5-HT) and then pump it back in through the serotonin transporter. Escitalopram blocks that transporter, so serotonin stays active in the gap between nerve cells for longer. The US label states that its antidepressant action is "presumed to be linked to potentiation of serotonergic activity" in the central nervous system (FDA label, 12.1). The word "presumed" is honest: why raising serotonin availability eventually improves mood and anxiety over weeks is still not fully understood. The NHS puts it more simply: it is "thought to work" by increasing serotonin levels (NHS).

The drug is highly selective. According to the UK SmPC, it binds with high affinity to the main site on the serotonin transporter and, with about 1,000-fold lower affinity, to a secondary "allosteric" site. It has no or low affinity for histamine, muscarinic (anticholinergic), adrenergic, dopamine, benzodiazepine and opioid receptors (SmPC 5.1). That selectivity is why it causes less sedation, dry mouth and blood-pressure drop than older tricyclic antidepressants.

What the body does with it

• Absorption: almost complete and unaffected by food. Peak blood levels come about 4–5 hours after a dose (SmPC 5.2; FDA label 12.3).
• Half-life: about 27–32 hours in the US label and about 30 hours in the SmPC. Steady-state levels are reached in about one week of once-daily dosing.
• Metabolism: mainly by the liver enzyme CYP2C19, with smaller contributions from CYP3A4 and CYP2D6. People who are genetically "poor metabolisers" via CYP2C19 have about twice the blood concentration of "extensive metabolisers" (SmPC 5.2).
• Older adults and liver disease: exposure (AUC) is about 50% higher in people over 65. In mild-to-moderate liver impairment the half-life roughly doubles and exposure is about 60% higher. These figures explain the lower UK dose caps (SmPC 5.2).

Why the heart rhythm matters

The QT interval is the part of the heartbeat when the heart's lower chambers electrically "reset". If it gets too long, a dangerous rhythm called torsade de pointes can occur. Escitalopram lengthens the QT interval in a dose-dependent way. In the healthy-volunteer ECG study reported by the MHRA, the corrected QT (QTc) rose 4.3 ms at 10 mg/day and 10.7 ms at 30 mg/day (MHRA). The US label reports 4.5 ms at 10 mg and 10.7 ms at 30 mg. It also predicts 6.6 ms at the 20 mg maximum dose (FDA label). Small average shifts matter most for people who already have risk factors.

What it is prescribed for

Licensed uses

Sources: Cipralex SmPC 4.1–4.2; FDA Lexapro label, section 1. The US paediatric GAD indication was added to the label in May 2023, according to the label's recent major changes.

Where guidelines place it

• Depression (NICE NG222, 2022): for a new episode of less severe depression, NICE says do not routinely offer antidepressants first line, only if that is the person's informed preference. For more severe depression, an antidepressant alone or combined with individual CBT is among the first-line options. NICE says SSRIs "are generally well tolerated, have a good safety profile and should be considered as the first choice for most people" (NICE NG222). NICE does not single out escitalopram over other SSRIs.
• Generalised anxiety disorder (NICE CG113): if a person chooses drug treatment, offer an SSRI and consider sertraline first "because it is the most cost-effective drug". If sertraline is ineffective, an alternative SSRI (such as escitalopram) or an SNRI is next (NICE CG113).
• Panic disorder (NICE CG113): "an SSRI licensed for panic disorder should be offered" unless otherwise indicated. NICE notes that escitalopram, sertraline, citalopram, paroxetine and venlafaxine are licensed for panic disorder (NICE CG113).
• Social anxiety disorder (NICE CG159): individual CBT is the preferred first treatment. For people who want medication, NICE says "offer a selective serotonin reuptake inhibitor (SSRI) (escitalopram or sertraline)". This makes escitalopram a named first-choice drug (NICE CG159).
• OCD (NICE CG31, 2005): the initial SSRI should be one of fluoxetine, fluvoxamine, paroxetine, sertraline or citalopram. Escitalopram is not on that list, even though it holds a UK OCD licence (NICE CG31).

What works and what does not

Benefits by claim

Depression: real, modest, and among the better-tolerated options

The most independent large-scale evidence is the 2018 Lancet network meta-analysis led by Andrea Cipriani. It pooled 522 double-blind randomised trials with 116,477 participants. It also drew on unpublished data from regulators, registries and companies, and the authors note they obtained "a considerable amount of unpublished data" for escitalopram specifically (Cipriani et al. 2018). Key numbers:

• Response versus placebo: OR 1.68 (95% CrI 1.50–1.87). All 21 antidepressants beat placebo, with ORs from 1.37 (reboxetine) to 2.13 (amitriptyline), so escitalopram sits in the middle-to-upper part of the range.
• Acceptability versus placebo: all-cause dropout OR 0.90 (0.80–1.02). This means people stopped escitalopram at about the same rate as placebo; the result was not statistically different.
• Head-to-head: escitalopram was among the drugs that were both more effective (range of ORs 1.19–1.96) and more tolerable (range 0.43–0.77) than other antidepressants.
• Certainty: GRADE certainty was rated "moderate for most of the comparisons involving … escitalopram" (Cipriani 2018).

What an odds ratio of 1.68 means in practice. An odds ratio compares the odds of responding (usually a 50% or greater fall in depression score) on the drug versus placebo. It is not the same as "68% more people get better". The authors themselves describe the effect sizes across antidepressants as "mostly modest" (Cipriani 2018). Placebo response in depression trials is substantial, so many people improve on placebo too. The drug adds a smaller extra increment on top of that.

Sponsorship and "novelty" effects. Cipriani and colleagues found that industry funding "was not associated with substantial differences" in response or dropout. They caution, though, that non-industry trials "were few". They also observed a "novelty effect": drugs looked better when they were new and tested as the experimental arm (Cipriani 2018). Escitalopram was a newer drug in many of its head-to-head trials, so part of its comparative advantage could reflect that bias.

Escitalopram versus citalopram. Lundbeck developed escitalopram as a single-enantiomer successor to its own citalopram. The 2009 Cochrane review found escitalopram more effective than citalopram for acute response (OR 0.67, 95% CI 0.50–0.87, in favour of escitalopram) and remission (OR 0.53, 0.30–0.93). However, it also reports that "all the studies" comparing escitalopram with other SSRIs "were sponsored by the drug company marketing escitalopram". Because of this, the authors "could not formally examine" sponsorship bias and urge caution (Cipriani et al., Cochrane 2009). Our reading: the superiority claim over citalopram rests almost entirely on manufacturer-sponsored trials and should be graded weak to moderate.

Generalised anxiety disorder

The 2019 Lancet network meta-analysis by Slee and colleagues at University College London pooled 89 trials with 25,441 patients. Duloxetine, pregabalin, venlafaxine and escitalopram "were more efficacious than placebo with relatively good acceptability". Escitalopram reduced the Hamilton Anxiety Rating Scale (HAM-A) by 2.45 points more than placebo (95% CrI −3.27 to −1.63). The study received no funding (Slee et al. 2019). The HAM-A runs from 0 to 56, so a 2.45-point average extra improvement is modest. It is still consistent, and escitalopram achieved it with relatively good tolerability. Quetiapine had a bigger effect but was poorly tolerated, and benzodiazepines and paroxetine were also poorly tolerated.

The manufacturer's pooled data in the UK SmPC give an absolute picture. Across three similar GAD trials, 47.5% of escitalopram patients responded versus 28.9% on placebo, and 37.1% versus 20.8% reached remission (SmPC 5.1). By our arithmetic, that is roughly 19 extra responders per 100 people treated. That implies about 5 people need to be treated for one extra response. These are company-sponsored registration data, so treat them as an upper-end estimate.

Social anxiety, panic and OCD

For social anxiety disorder, the NICE-funded network meta-analysis found that SSRIs and SNRIs were the only drug class to beat pill placebo (SMD −0.44). Individual CBT had the largest effects and is recommended first. For people who decline therapy, "SSRIs show the most consistent evidence of benefit" (Mayo-Wilson et al. 2014). NICE then named escitalopram and sertraline as the first-choice SSRIs (NICE CG159).

For OCD, the NIHR-funded network meta-analysis found SSRIs as a class reduced Y-BOCS scores by 3.49 points versus placebo. It concluded that combining medication with psychotherapy is "likely to be more effective" than psychotherapy alone, at least in severe OCD (Skapinakis et al. 2016). The escitalopram-specific OCD and panic evidence we could verify comes from the manufacturer's registration trials summarised in the SmPC. For example, 20 mg separated from placebo on Y-BOCS at 12 weeks, and both 10 and 20 mg did so at 24 weeks (SmPC 5.1).

How long it takes

The UK SmPC states that 2–4 weeks are usually needed for an antidepressant response. For panic disorder, "maximum effectiveness is reached after about 3 months" (SmPC 4.2). NICE tells patients that the benefits of antidepressants "should be felt within 4 weeks". It also says treatment is typically taken for at least 6 months, including after symptoms go away (NICE NG222).

Risks and all side effects

FDA boxed warning: suicidal thoughts and behaviours

The US label carries the FDA's strongest warning. In summary, antidepressants increased the risk of suicidal thoughts and behaviours in paediatric and young adult patients in short-term studies. All antidepressant-treated patients should be closely monitored for clinical worsening and for new suicidal thoughts and behaviours. Lexapro is not approved for children under 7 (FDA label). The pooled data behind the warning covered about 77,000 adults and 4,500 children in placebo-controlled trials:

• Under 18: 14 additional patients with suicidal thoughts or behaviours per 1,000 treated
• 18–24: 5 additional per 1,000
• 25–64: 1 fewer per 1,000
• 65 and over: 6 fewer per 1,000

The label also notes that depression itself is a risk factor for suicide, and that maintenance trials show antidepressants delay the return of depression. NICE advises a review 1 week after starting for people aged 18 to 25, or wherever there is particular concern about suicide risk (NICE NG222). The UK SmPC also warns about akathisia, a distressing inner restlessness, in the first weeks. It adds that raising the dose "may be detrimental" if it appears (SmPC 4.4).

Common side effects (with placebo comparison)

The US label gives rates from placebo-controlled trials. The comparison with placebo shows how much of each effect is due to the drug (FDA label, Tables 2–3).

In depression trials, 6% stopped escitalopram because of side effects versus 2% on placebo. In GAD trials the figures were 8% versus 4% (FDA label 6.1). Trial questionnaires often under-capture sexual side effects. The FDA label says sexual function "may not be spontaneously reported" and asks prescribers to ask about it directly. The UK SmPC notes "reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs/SNRI" (SmPC 4.4).

The NHS lists these common effects: headaches, feeling or being sick, sweating, diarrhoea or constipation, joint or muscle pain, feeling dizzy, sleepy, anxious or restless, weight and appetite changes, sleep problems, and sexual problems. It adds that most ease after a couple of weeks (NHS). The UK SmPC lists weight increase and increased or decreased appetite as "common" (1–10 in 100), and weight decrease as "uncommon" (SmPC 4.8).

Serious risks

Less common or rarely reported effects in the UK SmPC include:

• bruxism (teeth grinding), panic attacks, confusion, fainting, tinnitus, fast heartbeat, nosebleeds, gastrointestinal bleeding, hair loss, rash and heavy periods (uncommon);
• aggression, depersonalisation, hallucinations and slow heartbeat (rare);
• hepatitis, low platelets, raised prolactin, urinary retention, priapism, movement disorders and postpartum haemorrhage (frequency not known).

Source: SmPC 4.8.

Withdrawal and discontinuation symptoms

Escitalopram does not cause addiction in the drug-seeking sense. The US label reports no drug-seeking behaviour in premarketing studies, while noting that abuse potential was not systematically studied (FDA label 9.2). The body does adapt to it, however, and stopping can cause withdrawal symptoms:

• How common: in clinical trials, adverse events on stopping occurred in about 25% of escitalopram patients versus 15% on placebo (SmPC 4.4). An independent 2024 meta-analysis of 79 studies found an incidence of 0.31 after stopping antidepressants and 0.17 after stopping placebo. It estimated that about 15% of people (1 in 6–7) have true discontinuation symptoms, with severe symptoms in 2.8% versus 0.6% on placebo. Escitalopram was among the antidepressants "associated with higher frequencies" of symptoms (Henssler et al. 2024).
• What they feel like: dizziness, "electric shock" sensations, sleep disturbance and vivid dreams, agitation or anxiety, nausea, tremor, confusion, sweating, headache, palpitations, irritability and visual disturbances (SmPC 4.4).
• How long: usually within 2 weeks, but "in some individuals they may be prolonged (2-3 months or more)" (SmPC). NICE similarly says symptoms usually go within 1–2 weeks but can last "several weeks, and occasionally several months" (NICE NG222).

All interactions

Tell every prescriber, dentist and pharmacist that you take escitalopram, including before buying over-the-counter painkillers or herbal remedies.

A note on regulatory differences: UK and EU product information makes all QT-prolonging medicines a contraindication with escitalopram. The current US label contraindicates only pimozide. It reports the QT study data in its pharmacology section and lists QT prolongation and torsade de pointes under overdose and postmarketing reports (FDA label; SmPC). The stricter UK/EU position follows a Europe-wide review of the dose-dependent QT data (MHRA).

Who should avoid escitalopram

Do not use (contraindications)

• Allergy to escitalopram, citalopram or any tablet ingredient (FDA label 4)
• Taking an MAOI, linezolid or pimozide (see interactions)
• Known QT prolongation or congenital long QT syndrome, or taking other QT-prolonging medicines (UK) (SmPC 4.3)

Needs specialist caution

The NHS says escitalopram may not be suitable if you have any of the following (NHS):

• a past serious reaction to any antidepressant
• heart rhythm problems or heart disease
• a bleeding disorder, especially gut bleeding
• kidney or liver problems
• diabetes
• epilepsy
• glaucoma
• a history of mania

The MHRA adds significant bradycardia, recent heart attack and decompensated heart failure. It says an ECG review should be considered first in people with cardiac disease (MHRA). The SmPC advises caution in people who have electroconvulsive therapy (ECT), because clinical experience with the combination is limited (SmPC 4.4).

Children and young people

In the UK, escitalopram "should not be used" in under-18s. The SmPC notes more suicide-related behaviour and hostility in paediatric antidepressant trials, and a lack of long-term data on growth and development (SmPC 4.2, 4.4). In the US it is approved for depression from age 12 and GAD from age 7. The label advises monitoring weight and growth in children taking SSRIs (FDA label 8.4).

Pregnancy and breastfeeding

• Pregnancy: the NHS says escitalopram "can be used during pregnancy if needed" at the lowest effective dose. Delivery in hospital is usually advised so that mother and baby can be monitored (NHS). The UK SmPC gives the following figures (SmPC 4.6):
  • SSRI use late in pregnancy may raise the risk of persistent pulmonary hypertension of the newborn (PPHN) to about 5 per 1,000 pregnancies, against 1–2 per 1,000 in the general population.
  • Exposure in the month before birth is linked to a less than 2-fold increase in postpartum haemorrhage.
  • Newborns may show adaptation symptoms such as breathing difficulty, jitteriness and feeding problems.
  The US label adds that published data "have not established an increased risk of major birth defects or miscarriage". It also notes that women who stop antidepressants are more likely to relapse (FDA label 8.1). Abrupt stopping during pregnancy should be avoided.
• Breastfeeding: the sources differ. The UK SmPC says breastfeeding "is not recommended during treatment" (SmPC 4.6). The NHS says escitalopram "is sometimes used while breastfeeding" when benefits outweigh risks, although a switch may be suggested (NHS). This is an individual decision to make with a prescriber.

Older adults (65+)

Exposure is about 50% higher in older adults, and the UK caps the dose at 10 mg (MHRA). The 2023 AGS Beers Criteria make three points about SSRIs in older adults (AGS Beers 2023):

• In people with a history of falls or fractures, SSRIs should be avoided "unless safer alternatives are not available".
• SSRIs "may exacerbate or cause SIADH or hyponatremia", so sodium should be monitored closely when starting or changing doses.
• Warfarin plus SSRIs should be avoided where possible.

Liver and kidney disease

In mild-to-moderate liver impairment the UK starts at 5 mg for two weeks, with a maximum of 10 mg. Severe liver impairment needs extra-careful titration. No dose change is needed for mild-to-moderate kidney impairment, but caution is advised below a creatinine clearance of 30 mL/min (SmPC 4.2).

Dosage and how to take it

Your prescriber sets and adjusts your dose. The ranges below are the official licensed adult ranges, reproduced for information only. They are not a recommendation for any individual.

Sources: Cipralex SmPC 4.2; FDA label section 2; MHRA maximum-dose table. The SmPC states that the "safety of daily doses above 20 mg has not been demonstrated."

How to take it

Escitalopram is taken once a day, morning or evening, with or without food (FDA label 2.3). The NHS gives these instructions for each form (NHS):

• swallow tablets whole with water;
• let orodispersible tablets dissolve on the tongue;
• count liquid drops into a glass of water or orange or apple juice.

If you miss a dose, take it when you remember unless it is nearly time for the next one. Never take two doses to make up. If you have taken more than prescribed, the NHS says to call 111 (NHS). Overdose can cause seizures and heart-rhythm disturbances, and the US label recommends prolonged cardiac monitoring (FDA label 10).

How long to take it, and how to stop

For depression, the NHS says people will "probably need to keep taking it for 6 months or more" (NHS). NICE's typical course is at least 6 months, including after remission, with regular reviews (NICE NG222). For social anxiety disorder, the SmPC recommends 12 weeks to consolidate a response (SmPC).

Stopping must be gradual and supervised. The sources set different minimum paces:

• UK SmPC: reduce over "at least one to two weeks". Its warnings section advises tapering "over a period of several weeks or months, according to the patient's needs" (SmPC 4.2, 4.4).
• NICE: the speed of withdrawal should be "led by and agreed with the person", and withdrawal "may take weeks or months to complete successfully". If symptoms are severe, NICE says to consider going back to the previous dose, then reducing more slowly with smaller steps (NICE NG222).
• NHS: "your doctor will gradually reduce your dose over several weeks or months" (NHS).

Follow the money: who makes it and who funded the evidence

Who makes and owns it

• Originator: H. Lundbeck A/S, founded in 1915 and headquartered in Copenhagen, Denmark. Lundbeck describes itself as focused on brain diseases (Lundbeck Foundation statutes; Lundbeck).
• Controlling owner: the Lundbeck Foundation (Lundbeckfonden), a Danish commercial foundation established by Grete Lundbeck under statutes dated 4 March 1954. As at 26 March 2026 it held 69% of the share capital and 76% of the votes in H. Lundbeck A/S; the remaining shares trade on Nasdaq Copenhagen.
  • The foundation's statutes set out two objects: to "consolidate and expand the activities of the LUNDBECK GROUP", and to make distributions.
  • Those distributions include support for scientific projects and for research within the Lundbeck Group.
  Sources: Lundbeck Foundation statutes; Lundbeck Foundation. Factually, this means the foundation is both a major Danish research funder and the controlling owner of the company that sells Cipralex/Lexapro. Research the foundation funds on Lundbeck products therefore has an indirect commercial connection. We did not identify Lundbeck Foundation funding behind any of the key efficacy sources used in this article.
• US rights: Lexapro's US application (NDA 021323, approved 2002) is now listed under AbbVie, and the current label is issued by Allergan, an AbbVie company (Drugs@FDA; FDA label). In the 2000s, Lexapro was marketed in the US by Forest Laboratories of New York (Forest SEC filing, 2010).
• Revenue: in 2025 Lundbeck reported Cipralex/Lexapro revenue of DKK 1,955 million, down 2% at constant exchange rates. That was about 8% of the group's DKK 24,630 million total revenue, and 65% of it came from International Operations and 35% from Europe (Lundbeck FY2025 release). Lundbeck classes it as a "mature brand" now facing generic competition.
• Generics: dozens of manufacturers and repackagers now supply escitalopram in the US (openFDA). Most people are prescribed generic products, and generic makers have no special stake in the research on the original brand.

Who funded the evidence

• Registration (licensing) trials: the placebo-controlled trials described in the US label and UK SmPC were submitted by the licence holders. The label does not name the sponsors, so we treat these as company-generated data.
• Head-to-head comparisons: the Cochrane review found that "the large majority of included studies were sponsored by the manufacturer of escitalopram". This included every trial against another SSRI, and five of eight against newer antidepressants. Two further trials were sponsored by the marketer of bupropion XR and one by the marketer of duloxetine (Cochrane 2009).
• Independent syntheses: the reviews used for the main effect sizes were funded as follows.
  • Cipriani 2018: UK NIHR and the Japan Society for the Promotion of Science. One author declared honoraria from Lundbeck among several companies; the funder had no role.
  • Slee 2019: no funding.
  • Mayo-Wilson 2014: NICE.
  • Skapinakis 2016: NIHR.
  • Henssler 2024: no funding.
  These independent reviews broadly confirm that escitalopram works better than placebo. The independent evidence is less decisive on claims that it is superior to other antidepressants.
• Safety evidence: the QT restrictions came from regulators (MHRA and a Europe-wide review), not from the company (MHRA).

Documented integrity events

• EU "pay-for-delay" fine (citalopram, 2013): the European Commission fined Lundbeck €93.8 million. Under 2002 agreements, Lundbeck had made payments and other inducements to generic companies, which delayed their entry with cheaper generic citalopram, Lundbeck's then best-selling antidepressant (European Commission, 2013). The General Court upheld the decision in 2016. On 25 March 2021 the EU Court of Justice dismissed Lundbeck's and the generic companies' appeals (CJEU press release 49/21). This case concerned citalopram, the predecessor molecule, not escitalopram's clinical evidence.
• US marketing settlement (Forest Laboratories, 2010): Forest, then the US marketer, agreed to plead guilty to three charges:
  • a misdemeanour for off-label promotion of Celexa (citalopram) for paediatric patients;
  • a misdemeanour for distributing Levothroid, an unapproved drug;
  • a felony for obstruction relating to an FDA inspection.
  It also agreed to resolve civil False Claims Act allegations about off-label paediatric promotion of Celexa and Lexapro between 1998 and 2005, with payments of about $149 million plus interest. Forest "expressly denies the allegations" in the civil claims. It had set aside reserves of $313 million for the overall resolution (Forest Laboratories SEC 8-K, September 2010). Forest was the US marketing company, not Lundbeck.

These events are reported because they concern how the medicines were marketed and priced. They do not by themselves show that the clinical trial results for escitalopram are wrong. The independent, publicly funded meta-analyses above reach broadly similar conclusions about benefit over placebo.

Related research

• Stress, anxiety and depression prevention guide: the non-drug foundations (CBT skills, exercise, sleep, support)
• Stress, anxiety and depression supplements: the evidence
• St John's wort: must not be combined with escitalopram
• Saffron for depression
• L-theanine
• Magnesium: relevant to QT safety when levels are low
• Ashwagandha: evidence and safety
• Rhodiola
• Sleep prevention guide and sleep supplements evidence: insomnia is a common early side effect
• Melatonin
• Sibling medicine reviews: sertraline, citalopram, fluoxetine, paroxetine, venlafaxine, duloxetine, mirtazapine, pregabalin

Frequently asked questions

Sources and funding notes

• NHS. Escitalopram (medicine page), reviewed 18 June 2026: NHS England, UK public body; no commercial funding.
• Lexapro (escitalopram) US prescribing information, including the boxed warning, DailyMed SPL version 45: written by Allergan (an AbbVie company) and approved by the US FDA; trial data are company-generated.
• US FDA. Drugs@FDA, NDA 021323 (Lexapro): US government regulator; approval 14 August 2002; applicant now AbbVie.
• Cipralex 5/10/20 mg film-coated tablets, Summary of Product Characteristics (emc; text revised 05/2025): licence holder Lundbeck Limited (UK subsidiary of the Danish manufacturer); content approved by the UK regulator.
• MHRA. Citalopram and escitalopram: QT interval prolongation. Drug Safety Update, December 2011: UK government regulator, following a Europe-wide review.
• Cipriani A et al. Comparative efficacy and acceptability of 21 antidepressant drugs for major depressive disorder: a network meta-analysis. Lancet 2018: funded by NIHR Oxford Health Biomedical Research Centre (UK) and Japan Society for the Promotion of Science; the funder had no role. Declarations include industry fees for some authors (one listed Lundbeck).
• Slee A et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 2019: University College London; "No funding was received"; individual author declarations not verified (paywalled); erratum published.
• Cipriani A et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009: internal support from the University of Verona (Italy), no external funding. One author declared industry research and speaking fees (companies other than Lundbeck). Nearly all included trials were sponsored by the escitalopram marketer.
• NICE NG222. Depression in adults: treatment and management (2022): UK public body.
• NICE CG113. Generalised anxiety disorder and panic disorder in adults: UK public body; some recommendations date from 2004–2011, amended 2020.
• NICE CG159. Social anxiety disorder: recognition, assessment and treatment: UK public body.
• NICE CG31. Obsessive-compulsive disorder and body dysmorphic disorder: treatment (2005): UK public body.
• Mayo-Wilson E et al. Psychological and pharmacological interventions for social anxiety disorder in adults: network meta-analysis. Lancet Psychiatry 2014: funded by NICE; UK academic authors.
• Skapinakis P et al. Pharmacological and psychotherapeutic interventions for OCD in adults: network meta-analysis. Lancet Psychiatry 2016: funded by the UK National Institute for Health Research.
• Henssler J et al. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry 2024: German academic authors; no funding; no competing interests declared; errata published.
• American Geriatrics Society 2023 updated AGS Beers Criteria. J Am Geriatr Soc 2023: US professional society; "no sponsor for this paper".
• Lundbeck Foundation. Statutes and history: owner's own document (Denmark); used for ownership facts only.
• Lundbeck Foundation. H. Lundbeck A/S (strategic ownership): owner's own page; ownership facts only.
• H. Lundbeck A/S. Organization and ownership: manufacturer's own page; used for headquarters and ownership only.
• H. Lundbeck A/S. Corporate release for full year 2025 (4 February 2026): manufacturer's stock-exchange disclosure; used for revenue figures only.
• European Commission. Antitrust: Commission fines Lundbeck and other pharma companies for delaying market entry of generic medicines (IP/13/563, 19 June 2013): EU competition authority.
• Court of Justice of the European Union. Press release No 49/21 (25 March 2021), Lundbeck v Commission and related cases: EU court.
• Forest Laboratories, Inc. Form 8-K Exhibit 99 (15 September 2010), settlement of US government investigations: company's own mandatory SEC filing; used for the settlement facts; the company denied the civil allegations.
• openFDA drug label database query: escitalopram prescription labellers: US FDA public data; counted September 2026.

Last reviewed: 26 September 2026. Educational information from Pure City Research, not medical advice. Medicine decisions belong with a qualified prescriber.